Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betalutin with Rituximab in Relapsed/Refractory Follicular Lymphoma
NCT03806179Phase 1Completed
- Sponsor
- Nordic Nanovector ASA
- Start
- Oct 2018
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of lutetium (177Lu) lilotomab satetraxetan in follicular lymphoma (FL) (2 arms), sponsored by Nordic Nanovector ASA. Primary endpoint: Frequency and Severity of Adverse Events at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03806179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806179.